Literature DB >> 10433498

Interactions between cholecystokinin and opioids in the isolated guinea-pig ileum.

L Romanelli1, M C Amico, F Mattioli, L A Morrone, P Valeri.   

Abstract

1. Although cholecystokinin octapeptide sulphate (CCK-8) activates the opioid system of isolated guinea-pig ileum (GPI) whether it activates the mu- or kappa-system, or both, remains unclear. Neither is it known whether CCK-8 influences the withdrawal responses in GPI preparations briefly exposed to opioid agonists. This study was designed to clarify whether CCK-8 activates mu- or kappa-opioid systems or both; and to investigate its effect on the withdrawal contractures in GPI exposed to mu- or kappa-agonists and on the development of tolerance to the withdrawal response. 2. In GPI exposed to CCK-8, the selective kappa-antagonist nor-binaltorphimine elicited contractile responses that were concentration-related to CCK-8 whereas the selective mu-antagonist cyprodime did not. 3. In GPI preparations briefly exposed to the selective mu-agonist, dermorphin, or the selective kappa-agonist, U-50, 488H, and then challenged with naloxone, CCK-8 strongly enhanced the withdrawal contractures. 4. During repeated opioid agonist/CCK-8/opioid antagonist tests tolerance to opioid-induced withdrawal responses did not develop. 5. These results show that CCK-8 preferentially activates the GPI kappa-opioid system and antagonizes the mechanism(s) that control the expression of acute dependence in the GPI.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433498      PMCID: PMC1566095          DOI: 10.1038/sj.bjp.0702621

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  51 in total

1.  mu-opioid receptor activation inhibits N- and P-type Ca2+ channel currents in magnocellular neurones of the rat supraoptic nucleus.

Authors:  B L Soldo; H C Moises
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

2.  Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes.

Authors:  Z B You; O Godukhin; M Goiny; I Nylander; U Ungerstedt; L Terenius; T Hökfelt; M Herrera-Marschitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-05       Impact factor: 3.000

3.  A possible role for prostaglandins in the expression of morphine dependence in guinea-pig isolated ileum.

Authors:  M A Johnson; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

4.  On the mechanism(s) of cholecystokinin (CCK): receptor stimulation attenuates morphine dependence in mice.

Authors:  M Rezayat; N Azizi; M R Zarrindast
Journal:  Pharmacol Toxicol       Date:  1997-09

5.  Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718.

Authors:  C T Dourish; D Hawley; S D Iversen
Journal:  Eur J Pharmacol       Date:  1988-03-15       Impact factor: 4.432

6.  Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists.

Authors:  P S Portoghese; A W Lipkowski; A E Takemori
Journal:  Life Sci       Date:  1987-03-30       Impact factor: 5.037

7.  Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin.

Authors:  A E Panerai; L C Rovati; E Cocco; P Sacerdote; P Mantegazza
Journal:  Brain Res       Date:  1987-04-28       Impact factor: 3.252

8.  Mu-opioid and GABA(B) receptors modulate different types of Ca2+ currents in rat nodose ganglion neurons.

Authors:  K I Rusin; H C Moises
Journal:  Neuroscience       Date:  1998-08       Impact factor: 3.590

9.  Neural activation of opioid mechanisms in guinea pig ileum by excitatory peptides.

Authors:  J Garzón; V Höllt; P Sánchez-Blázquez; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1987-02       Impact factor: 4.030

10.  Withdrawal responses of guinea-pig isolated ileum following brief exposure to opiates and opioid peptides.

Authors:  L A Chahl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.